Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.

Gao Y, de Wit M, Struys EA, van der Linde HCZ, Salomons GS, Lamfers MLM, Willemsen R, Sillevis Smitt PAE, French PJ.

PLoS One. 2018 Jun 28;13(6):e0199737. doi: 10.1371/journal.pone.0199737. eCollection 2018.

2.

Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.

van den Bossche WBL, Kleijn A, Teunissen CE, Voerman JSA, Teodosio C, Noske DP, van Dongen JJM, Dirven CMF, Lamfers MLM.

Neuro Oncol. 2018 Oct 9;20(11):1494-1504. doi: 10.1093/neuonc/noy082.

PMID:
29796615
3.

Cerebrospinal fluid biomarkers of malignancies located in the central nervous system.

Verheul C, Kleijn A, Lamfers MLM.

Handb Clin Neurol. 2017;146:139-169. doi: 10.1016/B978-0-12-804279-3.00010-1. Review.

PMID:
29110768
4.

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.

Kleijn A, van den Bossche W, Haefner ES, Belcaid Z, Burghoorn-Maas C, Kloezeman JJ, Pas SD, Leenstra S, Debets R, de Vrij J, Dirven CMF, Lamfers MLM.

Mol Ther Oncolytics. 2017 Mar 1;5:11-19. doi: 10.1016/j.omto.2017.02.002. eCollection 2017 Jun 16.

5.

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.

Venkatesan S, Hoogstraat M, Caljouw E, Pierson T, Spoor JK, Zeneyedpour L, Dubbink HJ, Dekker LJ, van der Kaaij M, Kloezeman J, Berghauser Pont LM, Besselink NJ, Luider TM, Joore J, Martens JW, Lamfers ML, Sleijfer S, Leenstra S.

Oncotarget. 2016 Sep 6;7(36):58435-58444. doi: 10.18632/oncotarget.11205.

6.

Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells.

Balvers RK, Dirven CM, Leenstra S, Lamfers ML.

Curr Cancer Drug Targets. 2017;17(3):255-266. doi: 10.2174/1568009616666160813191809. Review.

PMID:
27528360
7.

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells.

Kleijn A, Kloezeman JJ, Balvers RK, van der Kaaij M, Dirven CM, Leenstra S, Lamfers ML.

Stem Cells Int. 2016;2016:5623235. doi: 10.1155/2016/5623235. Epub 2016 May 5.

8.

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Venkatesan S, Lamfers ML, Dirven CM, Leenstra S.

CNS Oncol. 2016;5(2):77-90. doi: 10.2217/cns-2015-0005. Epub 2016 Mar 17. Review. Erratum in: CNS Oncol. 2016 Jul;5(3):188.

9.

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors.

Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ, Idbaih A, Alentorn A, Kloezeman JJ, Lamfers MLM, Bollen AW, Taylor BS, Molinaro AM, Olshen AB, Chang SM, Song JS, Costello JF.

Cancer Cell. 2015 Sep 14;28(3):307-317. doi: 10.1016/j.ccell.2015.07.012.

10.

In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.

Berghauser Pont LM, Balvers RK, Kloezeman JJ, Nowicki MO, van den Bossche W, Kremer A, Wakimoto H, van den Hoogen BG, Leenstra S, Dirven CM, Chiocca EA, Lawler SE, Lamfers ML.

Gene Ther. 2015 Dec;22(12):947-59. doi: 10.1038/gt.2015.72. Epub 2015 Jul 21.

PMID:
26196249
11.

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.

Berghauser Pont LM, Kleijn A, Kloezeman JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven CM, Lamfers ML.

PLoS One. 2015 May 18;10(5):e0127058. doi: 10.1371/journal.pone.0127058. eCollection 2015.

12.

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.

Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S.

J Transl Med. 2015 Feb 26;13:74. doi: 10.1186/s12967-015-0427-y.

13.

Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.

de Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, Hol EM, Kroonen J, Robe PA, Lamfers ML, Schilham MW, Broekman ML.

Int J Cancer. 2015 Oct 1;137(7):1630-42. doi: 10.1002/ijc.29521. Epub 2015 Apr 7.

14.

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Söderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF.

Acta Neuropathol. 2015 Apr;129(4):597-607. doi: 10.1007/s00401-015-1403-6. Epub 2015 Feb 28.

15.

Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G.

Radiology. 2015 Jun;275(3):746-54. doi: 10.1148/radiol.14140251. Epub 2015 Feb 13.

16.

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.

Berghauser Pont LM, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, van der Spek PJ, Lamfers ML, Leenstra S.

Genes Cancer. 2014 Nov;5(11-12):445-59.

17.

Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue.

Bouwens TA, Trouw LA, Veerhuis R, Dirven CM, Lamfers ML, Al-Khawaja H.

J Neuroimmunol. 2015 Jan 15;278:271-6. doi: 10.1016/j.jneuroim.2014.11.016. Epub 2014 Nov 18.

18.

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.

Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M, van Gent DC, Dirven CM, Kanaar R, Lamfers ML, Leenstra S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):525-35. doi: 10.1016/j.canlet.2014.09.049. Epub 2014 Oct 8.

PMID:
25305451
19.

Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Belcaid Z, Lamfers ML, van Beusechem VW, Hoeben RC.

Hum Gene Ther. 2014 Oct;25(10):875-84. doi: 10.1089/hum.2014.092. Epub 2014 Sep 17. Review.

20.

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.

Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML.

Viruses. 2014 Aug 12;6(8):3080-96. doi: 10.3390/v6083080.

Supplemental Content

Loading ...
Support Center